2017
Genomic risk prediction of aromatase inhibitor‐related arthralgia in patients with breast cancer using a novel machine‐learning algorithm
Reinbolt R, Sonis S, Timmers C, Fernández‐Martínez J, Cernea A, de Andrés‐Galiana E, Hashemi S, Miller K, Pilarski R, Lustberg M. Genomic risk prediction of aromatase inhibitor‐related arthralgia in patients with breast cancer using a novel machine‐learning algorithm. Cancer Medicine 2017, 7: 240-253. PMID: 29168353, PMCID: PMC5773952, DOI: 10.1002/cam4.1256.Peer-Reviewed Original ResearchRandomized placebo-controlled pilot trial of omega 3 fatty acids for prevention of aromatase inhibitor-induced musculoskeletal pain
Lustberg M, Orchard T, Reinbolt R, Andridge R, Pan X, Belury M, Cole R, Logan A, Layman R, Ramaswamy B, Wesolowski R, Berger M, Patterson E, Loprinzi C, Shapiro C, Yee L. Randomized placebo-controlled pilot trial of omega 3 fatty acids for prevention of aromatase inhibitor-induced musculoskeletal pain. Breast Cancer Research And Treatment 2017, 167: 709-718. PMID: 29101597, PMCID: PMC5809189, DOI: 10.1007/s10549-017-4559-z.Peer-Reviewed Original ResearchConceptsQuality of lifeJoint symptomsRandomized placebo-controlled pilot trialBrief Pain Inventory-Short FormPostmenopausal breast cancer patientsRed blood cell (RBC) nPlacebo-controlled pilot trialFACT-ES scoresPlacebo-controlled studyPain severity scoreBreast cancer survivorsBreast cancer patientsAnti-inflammatory propertiesAdjuvant AICommon toxicitiesFACT-ESPurposeAromatase inhibitorsPrimary endpointDrug adherencePill countSecondary outcomesMusculoskeletal painTreatment armsCancer survivorsFatty acidsGait, balance, and patient-reported outcomes during taxane-based chemotherapy in early-stage breast cancer patients
Monfort S, Pan X, Patrick R, Ramaswamy B, Wesolowski R, Naughton M, Loprinzi C, Chaudhari A, Lustberg M. Gait, balance, and patient-reported outcomes during taxane-based chemotherapy in early-stage breast cancer patients. Breast Cancer Research And Treatment 2017, 164: 69-77. PMID: 28374323, PMCID: PMC5510549, DOI: 10.1007/s10549-017-4230-8.Peer-Reviewed Original ResearchConceptsBreast cancer patientsPatient-reported outcomesTaxane-based chemotherapyCancer patientsChemotherapy cyclesEarly-stage breast cancer patientsPatient-reported symptom severityDevelopment of CIPNSubsequent chemotherapy cyclesFirst chemotherapy cyclePatient-reported symptomsDose-limiting toxicityOutpatient oncology clinicsSelf-reported symptomsTaxane infusionTaxane therapyTaxane treatmentCIPN symptomsDose intensityPeripheral neuropathyOncology clinicPatient functionPhysical functionFunctional deficitsGait testing
2014
Stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction
Berger M, Vargo C, Vincent M, Shaver K, Phillips G, Layman R, Macrae E, Mrozek E, Ramaswamy B, Wesolowski R, Shapiro C, Lustberg M. Stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction. Supportive Care In Cancer 2014, 23: 2019-2024. PMID: 25519756, PMCID: PMC4804339, DOI: 10.1007/s00520-014-2556-x.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Agents, PhytogenicAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsDexamethasoneDiphenhydramineDrug Administration ScheduleDrug HypersensitivityFamotidineFemaleHumansInfusions, IntravenousMiddle AgedNeoplasm StagingPaclitaxelPremedicationProspective StudiesRetrospective StudiesConceptsInfusion hypersensitivity reactionPaclitaxel-based chemotherapyRescue medication useBreast cancer patientsHypersensitivity reactionsPaclitaxel dosesRescue medicationMedication useSecond doseCancer patientsBreast cancerLife-threatening complicationsMajority of patientsDoses of paclitaxelProspective pilot trialUse of paclitaxelBreast cancer treatmentPrimary endpointInfusion reactionsPremedication regimenSubsequent dosesUnwanted side effectsResultsIn totalPilot trialStudy population
2011
Phase II Trial of Neoadjuvant Exemestane in Combination With Celecoxib in Postmenopausal Women Who Have Breast Cancer
Lustberg M, Povoski S, Zhao W, Ziegler R, Sugimoto Y, Ruppert A, Lehman A, Shiels D, Mrozek E, Ramaswamy B, Layman R, Brueggemeier R, Shapiro C. Phase II Trial of Neoadjuvant Exemestane in Combination With Celecoxib in Postmenopausal Women Who Have Breast Cancer. Clinical Breast Cancer 2011, 11: 221-227. PMID: 21729671, PMCID: PMC3440773, DOI: 10.1016/j.clbc.2011.03.022.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAndrostadienesAntineoplastic AgentsBreast NeoplasmsCarcinoma, LobularCelecoxibCyclooxygenase 2Cyclooxygenase 2 InhibitorsDrug Therapy, CombinationFemaleFollow-Up StudiesHumansImmunoenzyme TechniquesLymphatic MetastasisMiddle AgedNeoadjuvant TherapyNeoplasm InvasivenessNeoplasm Recurrence, LocalNeoplasm StagingPostmenopausePyrazolesReceptor, ErbB-2Receptors, EstrogenReceptors, ProgesteroneSulfonamidesSurvival RateTreatment OutcomeConceptsPathological complete responsePhase II trialEstrogen receptorKi-67Neoadjuvant exemestaneII trialPostmenopausal womenCOX-2Breast cancerDefinitive breast cancer surgeryCOX-2 inhibitor celecoxibSerious cardiac eventsAnti-tumor responseBreast cancer surgeryAddition of celecoxibCOX-2 expressionMajority of womenStable diseaseCardiac eventsPartial responseComplete responseCancer surgeryCore biopsyAromatase inhibitorsHER-2
2010
Phase II Randomized Study of Two Regimens of Sequentially Administered Mitomycin C and Irinotecan in Patients with Unresectable Esophageal and Gastroesophageal Adenocarcinoma
Lustberg M, Bekaii-Saab T, Young D, Otterson G, Burak W, Abbas A, McCracken-Bussa B, Lustberg M, Villalona-Calero M. Phase II Randomized Study of Two Regimens of Sequentially Administered Mitomycin C and Irinotecan in Patients with Unresectable Esophageal and Gastroesophageal Adenocarcinoma. Journal Of Thoracic Oncology 2010, 5: 713-718. PMID: 20354452, PMCID: PMC3641556, DOI: 10.1097/jto.0b013e3181d7776d.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAntineoplastic Combined Chemotherapy ProtocolsBone NeoplasmsCamptothecinCarcinoma, Squamous CellEsophageal NeoplasmsEsophagogastric JunctionFemaleHumansIrinotecanLiver NeoplasmsLung NeoplasmsLymphatic MetastasisMaleMiddle AgedMitomycinNeoplasm StagingStomach NeoplasmsSurvival RateTreatment OutcomeConceptsMitomycin CDay 1Day 2Phase II Randomized StudyComplete pathologic responsePhase II evaluationGastroesophageal junction adenocarcinomaUnresectable esophagealEvaluable patientsGastroesophageal adenocarcinomaJunction adenocarcinomaPathologic responseRandomized studyArm AGastroesophageal junctionFuture trialsEsophageal cancerII evaluationSevere toxicityPatientsIrinotecanResponse ratePhase IAdenocarcinomaTopoisomerase 1
2007
Optimal Duration of Chemotherapy in Advanced Non-Small Cell Lung Cancer
Lustberg M, Edelman M. Optimal Duration of Chemotherapy in Advanced Non-Small Cell Lung Cancer. Current Treatment Options In Oncology 2007, 8: 38-46. PMID: 17634834, DOI: 10.1007/s11864-007-0020-6.Peer-Reviewed Original ResearchConceptsPlatinum-based chemotherapyQuality of lifeLung cancerNew agentsAdvanced non-small cell lung cancerOptimal durationNon-small cell lung cancerPlatinum-based combination chemotherapyEpidermal growth factor receptor inhibitorsGrowth factor receptor inhibitorsBenefit of chemotherapyFirst-line chemotherapyAdditional survival benefitAdvanced stage diseaseDuration of therapyMetastatic lung cancerCell lung cancerMatrix metalloproteinase inhibitorsCytotoxic regimenPlatinum doubletsLine chemotherapySequential therapyStage diseaseCombination chemotherapyOverall survival